University of Minnesota

Regenxbio Inc.

Metselex, Inc.

Walter C Low

Michael R Olin

John R Ohlfest

R Scott McIvor

Karen Kozarsky

Cyrus B Munshi

Michael D Finch

Carolyn Ann Fairbanks

Clifford Steer

Clairice Pearce

Matthew Chrostek

Nikolas Toman

Andrew Crane

Joseph Voth

Margaret A Wallenfriedman

Lan Chiang

Christopher J Sipe

Craig Bierle

Lalitha R Belur

Jian-Ping Wang

Cecilia M P Rodrigues

Mahendra Dc

Susana Dias Lucas De Oliveira

Walter A Hall

Cecilia Rodrigues

Susana Dias Lucas De Oliveria

Jing Xiao

Zhenhong Nan

Maple Shiao

John A Conrad

Maple Shaio

Eric P Flores

A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.

Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase

In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.

Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus

An apparatus includes a substrate and a plurality of biological material stimulators positioned on the substrate. Each biological material stimulator forms a fluctuating magnetic field capable of inducing a current in biological material.

Magnetic nanostimulator and nanosensor array for biological material stimulation and sensing

This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the bile acids such as ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA), and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium. Also disclosed are pharmaceutical compositions and methods of using the deuterated bile acids.

Deuterated bile acids

Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase

This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.

The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).

Therapeutic composition for treatment of glioblastoma

The invention relates generally to methods for isolation and culture of umbilical cord blood stem cells, cells isolated by the methods, and therapeutic uses for those cells.

Use of umbilical cord blood stem cells to treat ischemic event

A composition and method for inhibiting the growth and metastasis of breast tumors, including a tumor immunogen derived from breast tumor cells treated with an antisense oligonucleotide complementary to a gene or mRNA for the receptor for insulin-like growth factor type 1.

Insulin-like growth factor 1 receptors (IGF-1R) antisense

The invention provides compositions and methods for treating primary brain cancer. The compositions include at least one antisense oligonucleotide that inhibits the proliferation of primary brain cancer cells. The antisense oligonucleotides are preferably complementary to and hybridize to a mRNA encoding c-myb. A method of the invention involves treating patients with primary brain cancer with a pharmaceutical composition including at least one antisense oligonucleotide in an amount effective to inhibit primary brain cell proliferation. The invention also provides probes and primers useful to identify primary brain cells having amplified and/or rearranged genes encoding c-myb.

Antisense oligonucleotides and methods for treating central nervous

A method for inhibiting the growth of brain tumors comprising peripheral administration of GM-CSF in combination with brain tumor antigen.

GM-CSF administration for the treatment and prevention of recurrence of

Growing community of inventors

Minneapolis, MN, United States of America

Walter C Low